Intellia Therapeutics Inc 2022 Bradykinin Symposium Transcript
Good morning, and welcome to Intellia Therapeutics' investor event to discuss interim clinical updates across the company's in vivo pipeline. My name is Andrew, and I will be your conference operator today. Please be advised that this call is being recorded at the company's request. (Operator Instructions)
Following the formal remarks, we will open the call up for your questions. I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.
Thank you, operator, and good morning, everyone. Welcome to Intellia's investor webcast to discuss recent advances for our ongoing first-in-human studies of NTLA-2001 and NTLA-2002. Earlier today, we issued two press releases, detailing interim data from these clinical trials. The releases, along with an accompanying presentation for today's call can be found on the Investors & Media section of Intellia's website at intelliatx.com. As a reminder
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |